Soligenix, Inc. (SNGX)
After hours:
| Previous Close | 0.3926 |
| Open | 0.4000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3827 - 0.4050 |
| 52 Week Range | 0.3600 - 2.0000 |
| Volume | |
| Avg. Volume | 2,714,500 |
| Market Cap | 6.066M |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in the upcoming Annual Meeting of Stockholders to be held virtually at 9:00AM ET on May 23, 2024. "This Annual Meeting is exceedingly important to the Company," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of
- PR Newswire
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its compatibility study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice. The publication hig
- PR Newswire
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2024.
